Trial · NCT01599650
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO) | Baseline, 6 Months | analysis for change consists of the group that had a baseline and 6 month data point | letters | MEAN |
| SECONDARY | The Mean Average Change in Visual Acuity From Month 1 Through Month 24 Compared to Baseline | Baseline, 24 Months | analysis for change consists of the group that had a baseline and 24 month data point | letters | MEAN |
| SECONDARY | Number of Ranibizumab Treatments From Day 1 to Month 23 by Treatment Group | Day 1 through Month 23 | treatments | MEAN | |
| SECONDARY | Mean Average Change in Visual Acuity (BCVA Letters) From Month 1 Through Month 6 | From Baseline through Month 6 | letters | MEAN | |
| SECONDARY | The Mean Change in Visual Acuity BCVA (Letters) From Baseline at Month 12 and Month 24 | Baseline, Month 12 and Month 24 | Full Analysis set | letters | MEAN |
| SECONDARY | The Percent of Patients With a Visual Acuity Gain of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline up to Month 6 and Month 24, by Visit | Baseline, Month 6 and Month 24 | percent patients gaining improvement | NUMBER | |
| SECONDARY | Number of Patients With a BCVA Improvement vs Baseline or Achieving Greater Than or Equal to 73 Letters at Month 6 in the Study Eye | Month 6 | participants | NUMBER | |
| SECONDARY | Number of Patients With a BCVA Improvement vs Baseline or Achieved Greater Than or Equal to 73 Letters at Month 24 in the Study Eye | Month 24 | participants | NUMBER | |
| SECONDARY | The Mean Change in Central Reading Center-assessed Central Subfield Thickness From Month 12 and Month 24 vs. Baseline by Treatment Arm | Month 12 and Month 24 | microns | MEAN | |
| SECONDARY | The Mean Change in Patient Reported Outcomes in NEI-VFQ-25 Score (Composite Score and Subscales) at Month 6 and Month 24 Compared to Baseline | Months 6 and 24 | score on a scale | MEAN | |
| SECONDARY | BCVA (Letters) Mean Average Change From First Ranibizumab Treatment to Month 24 in the Study Eye for Patients Randomized to the Laser Monotherapy Arm | Month 24 | Randomized set | BCVA letters | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01599650/outcomes